Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Natalizumab biosimilar - Polpharma Biologics

Next Previous
Drug Profile

Natalizumab biosimilar - Polpharma Biologics

Alternative Names: DST-356A1; Natalizumab-sztn; PB-006; Tyruko

Latest Information Update: 23 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polpharma Biologics
  • Developer Polpharma Biologics; Sandoz
  • Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • Registered Crohn's disease

Most Recent Events

  • 14 Jan 2025 Sandoz announces intention to launch Natalizumab biosimilar in the US in 2025
  • 30 Jun 2024 Preregistration for Multiple sclerosis in Canada (unspecified route)
  • 01 Feb 2024 Launched for Multiple sclerosis in Germany (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top